Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

A careful reassessment of anthracycline use in curable breast cancer

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The evidence that motivated an independent review of breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A catalog of curated breast cancer genes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. DBCG Kvalitetsdatabase for Brystkræft – resumé af årsrapport 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelFormidling

  3. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Sara Alsterlind Hurvitz
  • Nicholas P McAndrew
  • Aditya Bardia
  • Michael F Press
  • Mark Pegram
  • John P Crown
  • Peter A Fasching
  • Bent Ejlertsen
  • Eric H Yang
  • John A Glaspy
  • Dennis J Slamon
Vis graf over relationer

It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of agents, leading some to question their widespread use, especially when newer agents with improved therapeutic indices have become available. Critically assessing when to incorporate an anthracycline is made more relevant in an era where molecular classification is enabling not only the development of biologically targeted therapeutics but also is improving the ability to better select those who would benefit from cytotoxic agents. This comprehensive analysis will present the problem of overtreatment in early-stage breast cancer, review evidence supporting the use of anthracyclines in the pre-taxane era, analyze comparative trials evaluating taxanes with or without anthracyclines in biologically unselected and selected patient populations, and explore published work aimed at defining anthracycline-sensitive tumor types.

OriginalsprogEngelsk
Artikelnummer134
TidsskriftCurrent Medical Literature. Breast Cancer
Vol/bind7
Udgave nummer1
Sider (fra-til)134
ISSN2374-4677
DOI
StatusUdgivet - 8 okt. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 68605024